Pan-Asian adaptation of the August 2025 ESMO guidelines for early and locally advanced NSCLC, agreed by experts from 10 Asian oncology societies, coordinated by ESMO and JSMO; voting was evidence-based, independent of drug access and reimbursement.
Guideline
Hayashi et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early and locally advanced non-small-cell lung cancer